Goodbye to reusable laparoscopes Welcome to Xenocor HD, a fog-free laparoscope
Xenocor HD
The Saberscope is the world's first true high-definition, fog-free, articulating, single-use laparoscope that has been cleared by the FDA. The current reusable laparoscope model has been in use for 35 years and is the only option for minimally invasive surgeons. However, there are issues with the current model that Xenocor aims to address.
The Saberscope eliminates fog, sees better through smoke and steam, and can articulate 90 degrees in any direction with a simple wrist movement, allowing the surgeon full visibility to the anatomy they need at any point during the procedure. The Saberscope system is FDA-cleared and is intended to be used in diagnostic and therapeutic procedures for endoscopy and endoscopic surgery within the thoracic and peritoneal cavities, including the female reproductive organs.
Charles DeCoster IV, CEO of Xenocor, shared that the company is focused on evolving the 35-year-old laparoscopic visualization model to something that clearly better serves caregivers and patients during minimally invasive surgery. He added that the FDA-cleared Saberscope improves visualization, dramatically diminishes workflow complexity, increases safety, and reduces waste.
Michael J. Hennessy Jr., GenHenn managing partner, expressed his excitement over leading the Xenocor Series A. He believes that Xenocor will have a transformational impact on minimally invasive surgery based on the deep insights he has gathered during his long career in healthcare leadership. He shared that their unique technology coupled with their veteran leadership will change the future of laparoscopy forever.
Xenocor's Saberscope offers a solution to the issues faced by the current reusable laparoscope model. With the funding secured from the Series A funding round, Xenocor can launch its flagship product and continue innovating for its customers.
According to John Evey, Managing Director of Growing Impact Ventures, the Xenoscope has the potential to replace expensive, inflexible legacy technologies, making laparoscopic surgery possible virtually anywhere. The Xenoscope provides both clinical and financial advantages that benefit surgeons, staff, healthcare facilities, and most importantly, patients. The technologies of the Xenoscope offer vastly improved image quality, eliminate cross-contamination, reduce technical complications and operation room downtimes, and are accessible to markets of varying sizes.
Growing Impact Ventures, LP is an impact venture fund focused on the advancement of private companies delivering technologies that enhance the health and welfare of people and communities worldwide. The fund invests directly in commercial entities offering innovative solutions that enhance the "foundational requirements" for human health, including effective sanitation systems, clean drinking water, reliable shelter, sustainable energy, vibrant marine environments, and adequate nutrition. The portfolio includes medical technology companies such as Second Heart Assist and Farapulse, as well as environmentally-focused entities such as Cibus, Aquacycl, and Noble Environmental Technologies.
Xenocor is a privately held corporation based in Salt Lake City, UT, and offers a suite of leading-edge, fog-free, disposable surgical technologies for minimally invasive, abdominal, and thoracic procedures. The products emerged from the Center for Medical Innovation at the University of Utah and are FDA cleared, CE marked, and patent-protected.
Evan Kelso, CEO of Xenocor, shared that the advanced features of the Xenoscope have the potential to dramatically upend laparoscopic surgical processes and expenditures in countries that spend an inordinate amount of resources on healthcare. These new capabilities can also quickly deliver a higher standard of care to those in countries that desperately need it. The focus now is to increase production and respond to the demand being experienced. The investment from Growing Impact Ventures facilitates a swift response.
In conclusion, the Xenoscope has the potential to revolutionize laparoscopic surgery by providing clinical and financial advantages that benefit everyone involved. Its innovative technologies offer vastly improved image quality, eliminate cross-contamination, reduce technical complications and operation room downtimes, and are accessible to markets of varying sizes. With the investment from Growing Impact Ventures, Xenocor can increase production and respond to the demand being experienced, enabling it to quickly deliver a higher standard of care to those in need.
